neurobo pharmaceuticals, inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. its therapeutics programs include nb-01 for the treatment of painful diabetic neuropathy; nb-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia. neurobo pharmaceuticals, inc. was incorporated in 2017 and is headquartered in boston, massachusetts.
Company profile
Ticker
NRBO
Exchange
Website
CEO
Jeong Gu Kang
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Gemphire Therapeutics Inc.
SEC CIK
Corporate docs
Subsidiaries
NeuroBo Therapeutics, Inc. • NeuroBo Co., Ltd. • ANA Therapeutics, LLC ...
NRBO stock data
Latest filings (excl ownership)
8-K
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
28 Mar 24
8-K
Blinded Safety Review Completed for the First 6 Months of the Phase 2a Clinical Trial Conduct; Recommending Trial Continue Without Modification
13 Mar 24
8-K
NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive
4 Mar 24
8-K
NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
29 Feb 24
8-K
Other Events
14 Feb 24
8-K
NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
1 Feb 24
8-K
Full Data Readout Expected in the Second Half of 2024
18 Jan 24
8-K
Other Events
9 Jan 24
8-K
NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
28 Dec 23
8-K
NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split
19 Dec 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 25.84 mm | 25.84 mm | 25.84 mm | 25.84 mm | 25.84 mm | 25.84 mm |
Cash burn (monthly) | 950.33 k | (no burn) | 1.30 mm | 1.73 mm | 938.00 k | 767.75 k |
Cash used (since last report) | 5.67 mm | n/a | 7.74 mm | 10.30 mm | 5.59 mm | 4.58 mm |
Cash remaining | 20.17 mm | n/a | 18.10 mm | 15.54 mm | 20.24 mm | 21.26 mm |
Runway (months of cash) | 21.2 | n/a | 13.9 | 9.0 | 21.6 | 27.7 |
Institutional ownership, Q2 2023
47.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 8 |
Opened positions | 3 |
Closed positions | 2 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 47.53 mm |
Total shares | 18.54 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Dong-a ST | 12.43 mm | $16.03 mm |
E&Investment | 6.02 mm | $2.74 mm |
BLK Blackrock | 42.22 k | $18.45 mm |
VIRT Virtu Financial | 23.87 k | $10.00 k |
Two Sigma Investments | 12.49 k | $5.46 mm |
Tower Research Capital | 11.05 k | $4.83 mm |
BAC Bank Of America | 8.00 | $3.00 k |
MS Morgan Stanley | 2.00 | $1.00 k |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Mar 24 | Marshall H Woodworth | Common Stock | Grant | Acquire A | No | No | 0 | 33,496 | 0.00 | 33,496 |
1 Dec 23 | Tursi James Patrick | Common Stock | Grant | Acquire A | No | No | 0 | 7,157 | 0.00 | 32,157 |
1 Dec 23 | Tursi James Patrick | Common Stock | Grant | Acquire A | No | No | 0 | 25,000 | 0.00 | 25,000 |
11 Aug 23 | Hyung Heon Kim | Common Stock | Grant | Acquire A | No | No | 0 | 625,064 | 0.00 | 625,064 |
News
NeuroBo Pharmaceuticals Appoints Marshall H. Woodworth As Chief Financial Officer, Effective March 1, 2024
4 Mar 24
Dow Jumps 250 Points; Honeywell Issues Weak Forecast
1 Feb 24
Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
1 Feb 24
12 Health Care Stocks Moving In Thursday's Intraday Session
1 Feb 24
Crude Oil Gains 1%; ISM Manufacturing PMI Tops Expectations
1 Feb 24
Press releases
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
28 Mar 24
NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
13 Mar 24
NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer
4 Mar 24
NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
29 Feb 24
NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference
12 Feb 24